In both olaparib- and paclitaxel-treated ovarian cancer cells, verapamil and elacridar MDR1 inhibitors can reverse ABCB1-mediated drug resistance, but the clinical trial outcome is poor. Here, ABCB1 is linked to ovarian cancer.